One drug carries the revenue. The next one just got complicated.
The heart of it Exelixis built a profitable business on a single cancer drug, cabozantinib, and spent years betting that...
The Quiet Compounder at a Loud Price: What Royalty Pharma’s Filings Actually Say
Royalty Pharma's stock sat at an all-time low in December 2024. By late August 2026, it had touched an all-time...
Receipts: Who Spends the Most Inventing Drugs?
Every number on our pharma R&D infographic, linked to the exact SEC filing it came from.
Evidence Sheet: Biogen (BIIB)
The standing BullScope yardsticks for Biogen, computed from official filings and refreshed with each new edition.
United Therapeutics: The Stock Is Priced for Stagnation. The Filings Tell a Different Story.
Two facts about United Therapeutics sit side by side right now and refuse to make peace. The company has grown...
Organon: The Company Earning More Per Sale Than Its Stock Suggests, With a Cloud Still Overhead
Organon was carved out of Merck in 2021 with a specific promise: take a portfolio of mature medicines, add a...
Boeing renews 364-day credit line as operating margin stays thin at 4.8%
Boeing has executed a new 364-day revolving credit agreement dated August 24, 2026, replacing its prior facility from August 25,...
Evidence Sheet: Zoetis (ZTS)
The standing BullScope yardsticks for Zoetis, computed from official filings and refreshed with each new edition.
Half the Price, Same Business: What Zoetis’s Filed Numbers Actually Say
Two years ago, Zoetis traded at roughly 35 times its annual earnings. Today it trades at roughly 12 times. The...
Biogen: The Stock That Priced In a Recovery the Margins Haven’t Filed Yet
Five years ago, Biogen's stock briefly traded above $425 on the back of an Alzheimer's drug that Medicare ultimately refused...
BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.